Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Salgia on Biomarker-Driven Therapies of Interest for Second-Line SCLC
July 30th 2025, 7:25pm
Bridging the Gaps in Lung Cancer
Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.
Dr Kim on the Collaborative, Forward-Thinking Nature of the 2025 BTG in Lung Cancer Meeting
July 30th 2025, 7:19pm
Bridging the Gaps in Lung Cancer
Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.
Dr Sen on the Role of Immunotherapy in SCLC
July 30th 2025, 6:40pm
Bridging the Gaps in Lung Cancer
Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.
Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC
July 28th 2025, 10:06pm
International Lung Cancer Congress
Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.
Efforts to Yield Greater OS Benefit With EGFR TKIs Continue in Early-Stage EGFR+ NSCLC
July 28th 2025, 9:14pm
International Lung Cancer Congress
Roy S. Herbst, MD, PhD, highlights the evolution of EGFR TKIs and the need for treatments improving DFS and OS outcomes in EGFR-mutant NSCLC.
How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive
July 28th 2025, 6:49pm
International Lung Cancer Congress
Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.
Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC
July 27th 2025, 12:00pm
International Lung Cancer Congress
Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.
Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer
July 26th 2025, 8:50pm
International Lung Cancer Congress
Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.
Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC
July 26th 2025, 8:40pm
International Lung Cancer Congress
Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.
Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC
July 26th 2025, 8:05pm
International Lung Cancer Congress
Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.
Dr Landgren on Considerations Surrounding the Current Treatment Paradigm for Smoldering Multiple Myeloma
July 26th 2025, 7:04pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.
Dr Danilov on Considerations in Frontline Treatment Selection for CLL
July 26th 2025, 6:26pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
Alexey Danilov, MD, PhD, discusses frontline treatment selection for chronic lymphocytic leukemia.
Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC
July 25th 2025, 11:35pm
International Lung Cancer Congress
Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.
Personalizing Treatment for Atypical EGFR-Mutated NSCLC
July 25th 2025, 7:37pm
International Lung Cancer Congress
Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.
Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLC
July 25th 2025, 7:20pm
International Lung Cancer Congress
Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.
Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC
July 25th 2025, 7:02pm
International Lung Cancer Congress
Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.
High-Risk Features Could Guide Treatment Intensification in First-Line EGFR-Mutated NSCLC
July 25th 2025, 6:39pm
International Lung Cancer Congress
Lyudmila A. Bazhenova, MD, discusses considerations for treatment intensification in patients with EGFR-mutated NSCLC.
Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC
July 24th 2025, 12:15am
Bridging the Gaps in Lung Cancer
Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.
Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC
July 23rd 2025, 11:55pm
Bridging the Gaps in Lung Cancer
Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.
Dr Shum on Evolving First-Line Treatment Approaches for EGFR-Mutant NSCLC
July 23rd 2025, 1:00am
Bridging the Gaps in Lung Cancer
Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.